solriamfetol (Sunosi)
Jump to navigation
Jump to search
Indications
- excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
Dosage
- 150 mg & 300 mg.
Adverse effects
- decreased appetite
- headache
- nausea
- nasopharyngitis
- xerostomia
- anxiety
- insomnia
- hypertension
- tachycardia[1][2] Solriamfetol can cause elevations in blood pressure and heart rate, s
Mechanism of action
- dopamine-norepinephrine reuptake inhibitor
- precise mechanism for treatment of excessive daytime sleepiness is unknown
More general terms
References
- ↑ 1.0 1.1 Monaco K. Solriamfetol Improves Wake-Time in Narcolepsy Types 1 and 2 Higher dosages showed greater improvements MedPage Today. April 25, 2018. https://www.medpagetoday.com/meetingcoverage/aan/72532
Thorpy M, et al A randomized, placebo-controlled, phase 3 study of the safety and efficacy of solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2). American Academy of Neurology (AAN) 2018; Abstract CT 003. - ↑ 2.0 2.1 Herman AO, Sofair A, Chavey WE FDA Approves Drug for Daytime Sleepiness in Those with Sleep Apnea, Narcolepsy Physician's First Watch, March 22, 2019 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org